|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Muzaffer Kahyaoğlu
Dr. Ahmet Karaduman
Contributors
Dr. Ahmet Karaduman
Dr. Berkant Öztürk
Dr. Burak Kardeşler
Dr. Kıvanç Eren
Dr. Mehmet Aydoğan
Dr. Murat Demirci
Dr. Murat Yiğitbaşı
Dr. Mustafa Candemir
Dr. Mustafa Lütfi Yavuz
Dr. Mustafa Yenerçağ
Dr. Ravza Betül Akbaş
Dr. Selvi Öztaş
Dr. Serkan Bulgurluoğlu
Dr. Yunus Çalapkulu
Dr. Yusuf Bozkurt
|
| |
|
|
|
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality OutcomesTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes (Dr. Selvi Öztaş)Dr. Selvi Öztaş
Name of the Study: Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes
Published in Congress: ESC 2024
Link: Nat Med (2024). https://doi.org/10.1038/s41591-024-03264-4
Objective:
Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
Methods:
In light of the strong epidemiological overlap and shared mechanistic drivers of clinical outcomes across cardio-kidney-metabolic syndrome, we summarize the efficacy and safety of finerenone on cardiovascular, kidney, and mortality outcomes in this prespecified participant-level pooled analysis.
Results:
The three trials included 18,991 participants (mean age 67?±?10 years; 35% women). During 2.9 years median follow-up, the primary outcome of cardiovascular death occurred in 421 (4.4%) assigned to finerenone and 471 (5.0%) assigned to placebo (HR 0.89; 95% CI 0.78-1.01; P?=?0.076). Death from any cause occurred in 1,042 (11.0%) participants in the finerenone arm and 1,136 (12.0%) in the placebo arm (HR 0.91; 95% CI 0.84-0.99; P?=?0.027). Finerenone further reduced the risk of HF hospitalization (HR 0.83; 95% CI 0.75-0.92; P?<?0.001) and the composite kidney outcome (HR 0.80; 95% CI 0.72-0.90; P?<?0.001).
Conclusion:
While this pooled analysis failed to demonstrate significant reductions in cardiovascular death, finerenone was associated with significantly lower deaths of any cause, cardiovascular events, and kidney outcomes.
Interpretations:
Although finerenone did not reveal a significant difference in the cardiovascular mortality outcomes of the study, similar to other studies, combining these data reveals the potential role of finerenone for treatment modification of the disease in the cardio-renal-metabolic spectrum.
|
